Disseminated on behalf of BioNxt Solutions Inc., may include paid advertisements. Investment Considerations Flagship drug candidate BNT23001 targets the $28B MS market with a faster-acting, easier-to-administer sublingual format. Additional candidates address MG, LN, RA, longevity, and diabetes/obesity using the same thin-film technology. Gen-Plus R&D integration accelerates development, manufacturing, and European commercialization. Patent portfolio spans major … Continue reading “BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF)”
 
							
							
							| Symbol | Release | Time | 
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |